Boyd Watterson Asset Management LLC OH Sells 150 Shares of Becton, Dickinson and Company (NYSE:BDX)

Boyd Watterson Asset Management LLC OH trimmed its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 58.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 106 shares of the medical instruments supplier’s stock after selling 150 shares during the quarter. Boyd Watterson Asset Management LLC OH’s holdings in Becton, Dickinson and Company were worth $26,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in BDX. WR Wealth Planners LLC increased its holdings in shares of Becton, Dickinson and Company by 1.4% during the second quarter. WR Wealth Planners LLC now owns 2,978 shares of the medical instruments supplier’s stock valued at $696,000 after acquiring an additional 42 shares in the last quarter. Clear Creek Financial Management LLC boosted its position in Becton, Dickinson and Company by 5.1% in the second quarter. Clear Creek Financial Management LLC now owns 900 shares of the medical instruments supplier’s stock valued at $210,000 after buying an additional 44 shares during the last quarter. Sound Income Strategies LLC raised its position in Becton, Dickinson and Company by 35.8% during the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 44 shares during the last quarter. Central Pacific Bank Trust Division increased its stake in shares of Becton, Dickinson and Company by 22.5% in the third quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier’s stock worth $59,000 after acquiring an additional 45 shares during the period. Finally, Capital Advisors Ltd. LLC lifted its holdings in Becton, Dickinson and Company by 3.6% during the second quarter. Capital Advisors Ltd. LLC now owns 1,394 shares of the medical instruments supplier’s stock valued at $326,000 after purchasing an additional 48 shares in the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $240.52 on Thursday. The stock has a market cap of $69.51 billion, a P/E ratio of 52.98, a price-to-earnings-growth ratio of 1.79 and a beta of 0.42. The company has a fifty day simple moving average of $237.33 and a 200-day simple moving average of $235.16. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $262.23.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.31 by $0.19. The company had revenue of $4.99 billion for the quarter, compared to analyst estimates of $5.08 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The business’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter last year, the company posted $2.96 earnings per share. Equities analysts expect that Becton, Dickinson and Company will post 13.11 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Stifel Nicolaus increased their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a report on Friday, July 26th. Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $255.00 to $275.00 in a research note on Tuesday, October 1st. Raymond James reduced their price objective on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. Finally, Evercore ISI raised their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $282.63.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.